A synthetic neuroactive heptapeptide combining an ACTH fragment with a Pro-Gly-Pro tripeptide, researched for nootropic actions, BDNF stimulation, and ischemic stroke recovery.
~15 - 20 minutes (rapid neural uptake and multi-hour genomic downstream activation)
Melanocortin Receptors (MC4R/MC5R)
C37H51N9O10S
Administered via intranasal spray to facilitate direct transport across the cribriform plate into cerebral spinal fluid.
Small or observational human data; warrants clinical caution.
Animal (rodent) and in-vitro cellular assays. Does NOT prove human efficacy.
Formal regulatory oversight and verified clinical development phase.
Evidence classification for Semax: Human clinical data is strictly differentiated from non-human animal and in-vitro laboratory assays.
C37H51N9O10S
Met-Glu-His-Phe-Pro-Gly-Pro
Semax was synthesized by the Institute of Molecular Genetics and the Brain Research Institute of the Russian Academy of Medical Sciences. It is an analog of adrenocorticotropic hormone (ACTH 4-10) without any hormonal or corticosteroid-inducing endocrine activity. Semax is widely used in Eastern European clinical neurology for acute ischemic stroke, traumatic brain injury, and cognitive decline.
Upregulates Brain-Derived Neurotrophic Factor (BDNF) and TrkB receptor mRNA expression in the hippocampus, modulates dopaminergic and serotonergic neurotransmission, and downregulates inflammatory gene networks following neural ischemia.
Peer-reviewed publications, clinical trials, and preclinical research investigating Semax.
Mechanistic molecular study illustrating how Semax confers neuroprotection during cerebral ischemia by robustly upregulating Brain-Derived Neurotrophic Factor (BDNF) and TrkB signaling.
Documented literature dosing intervals and published clinical trial protocols.
Biological delivery routes and standardized laboratory reconstitution principles.
Administered via intranasal spray to facilitate direct transport across the cribriform plate into cerebral spinal fluid.
Lyophilized peptides must be reconstituted using sterile bacteriostatic water (0.9% benzyl alcohol) and maintained strictly refrigerated between 2°C - 8°C (36°F - 46°F), shielded from light.
View Full Preparation ProtocolCompiled from peer-reviewed biomedical literature, public clinical trial registries, and recognized reference catalog databases.
Pharmacological profiles, receptor targets, and clinical data are verified against primary registries:
Community research topics, peptide nomenclature, and aliases are cross-referenced with public catalogs:
This topic was identified through research of publicly available peptide resources and peer-reviewed literature. Peptide Health Digest provides independent scientific explanations and does not endorse commercial distribution.
